Form 4: CG Oncology Director Leonard Post Executes Stock Option and Sells Shares Under 10b5-1 Plan

Director Leonard Post exercised stock options and sold shares of CG Oncology under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 17, 2025, Leonard Post, a director of CG Oncology, exercised a stock option to acquire 1,000 shares of common stock at a price of $0.60 per share.
• Simultaneously, Post sold 1,000 shares of common stock at a price of $28.00 per share.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on September 6, 2024.
• Following these transactions, Post directly owns 0 shares of common stock and 130,077 derivative securities.

Sentiment

Score: 5

Explanation: This is a neutral filing, simply reporting transactions. The use of a 10b5-1 plan suggests a planned approach to selling shares, which is neither particularly positive nor negative.

Future Outlook

There is no future outlook provided in this document.

Industry Context

This is a standard Form 4 filing, reflecting insider transactions. The use of a 10b5-1 plan suggests the insider is selling shares in a pre-planned manner to avoid accusations of trading on inside information. These filings are common and closely watched by investors for insights into management's perspective on the company's stock.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, but the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates